Tenet Healthcare now sees 2022 adjusted EBITDA above $3.425B guidance midpoint

Tenet Healthcare expects to exceed the midpoint of its latest FY22 Adjusted EBITDA outlook range. Anticipates its Adjusted EBITDA, excluding any Q4 stimulus grant income related to the pandemic, slightly above the mid-point of its Adjusted EBITDA guidance of $3.425B for 2022. "Our business units continued to demonstrate effective management capabilities and delivered strong results in Q4," said Saum Sutaria, CEO. "All three of our business units are expected to produce Adjusted EBITDA excluding grant income that was at or slightly above the mid-point of our guidance. We look forward to providing more details in a few weeks along with sharing plans to support a successful 2023."